Venlafaksin kullanımına bağlı akut distoni: Olgu sunumu

Antipsikotiklere bağlı ekstrapiramidal sendromlar iyi araştırılmış olmasına rağmen, antidepresanlara bağlı ekstrapiramidal sendromlar yeterince incelenmemiştir. Bugüne kadar yapılan araştırmalar daha çok Seçici Serotonin Gerialım İnhibitörleri ile ilgilidir. Antidepresan kullanımına bağlı ekstrapiramidal sendrom gelişimi için tanımlanmış risk faktörleri ileri yaş, kadın cinsiyet ve eş zamanlı kullanılan ilaçların CYP2D6 inhibisyonu etkileşimidir. Bu olgu klinik olarak son derece önemli ve müdahale gerektiren bir yan etki olan ekstrapiramidal sendromun, venlafaksin gibi bir Serotonin Noradrenalin Gerialım İnhibitörüne bağlı olarak da gelişebileceğini vurgulamak amacıyla sunulmuştur

Venlafaxine-induced acute dystonia: a case report

Although mechanisms underlying neuroleptic-induced extrapyramidal symptoms have been well researched, extrapyramidal symptoms associated with antidepressants are understudied. Research conducted to date is more concerned with selective serotonin reuptake inhibitors. Recognized risk factors for extrapyramidal symptoms associated with antidepressants are advancing age, female sex, and pharmacokinetic interaction of concurrently used drugs with CYP2D6 inhibition effect. This case is presented to emphasize that the occurrence of extrapyramidal symptoms, which are clinically important side effects requiring intervention, may be related with venlafaxine, a serotonin noradrenaline reuptake inhibitor

PDF

___

1. Madhusoodanan S, Alexeenko L, Sanders R, Brenner R. Extrapyramidal symptoms associated with antidepressants: a review of the literature and an analysis of spontaneous reports. Ann Clin Psychiatry 2010; 22:148-156.
2. Foster AR, Lancaster NP. Disturbance of motor function during treatment with imipramine. Br Med J 1959; 2:1452-1453. [CrossRef]
3. Gill HS, DeVane CL, Risch SC. Extrapyramidal symptoms associated with cyclic antidepressant treatment: a review of the literature and consolidating hypotheses. J Clin Psychopharmacol 1997; 17:377-389. [CrossRef]
4. Schillevoort I, Van Puijenbroek EP, de Boer A, Roos RA, Jansen PA, Leufkens HG. Extrapyramidal syndromes associated with selective serotonin reuptake inhibitors: a case-control study using spontaneous reports. Int Clin Psychopharmacol 2002; 17:75-79. [CrossRef]
5. Kapur S, Remington G. Serotonin-dopamine interaction and its relevance to schizophrenia. Am J Psychiatry 1996; 153:466-476. [CrossRef]
6. Coulter DM, Pillans PI. Fluoxetine and extrapyramidal side effects. Am J Psychiatry 1995; 152:122-125. [CrossRef]
7. Leo RJ. Movement disorders associated with the serotonin selective reuptake inhibitors. J Clin Psychiatry 1996; 57:449-454. [CrossRef]
8. Venlafaxine and extrapyramidal effects. http://www.lareb.nl/ LarebCorporateWebsite/media/publicaties/kwb_2004_2_venla. pdf. Accessed February 20, 2015.
9. Caley CF. Extrapyramidal reactions and the selective serotoninreuptake inhibitors. Ann Pharmacother 1997; 31:1481-1489.
10. Gerber PE, Lynd LD. Selective serotonin-reuptake inhibitorinduced movement disorders. Ann Pharmacother 1998; 32:692- 698. [CrossRef]
11. Hisli N. Validity and reliability of Beck Depression Inventory for university students. Journal of Psychology 1989; 7:3-13. (Turkish)
12. World Health Organization. ICD-10 Classification of Mental and Behavioural Disorders: Clinical Descriptions and Diagnostic Guidelines. Ozturk MO, Ulug B (Translation Editors) First ed, Ankara: Turkiye Sinir ve Ruh Sagligi Dernegi, 1993. (Turkish)
13. Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, Janecek E, Domecq C, Greenblatt DJ. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981; 30:239-245. [CrossRef]
14. Fonseca L, Rodrigues M, Machado A. Psychogenic movement disorder after a venlafaxine-induced dystonia. Mov Disord 2010; 25:506-507. [CrossRef]
15. Ng J, Sansone RA, McDonald S. Akathisia and abnormal movements of the upper extremities with venlafaxine and methimazole. Gen Hosp Psychiatry 2009; 31:388-390. [CrossRef]
16. George M, Campbell JJ 3rd. Venlafaxine causing akathisia: a case report. J Neuropsychiatry Clin Neurosci 2012; 24:E3-4. [CrossRef]
17. Lai CH. Venlafaxine-related akathisia side-effects and management in a depressed patient. Psychiatry Clin Neurosci 2013; 67:127-128. [CrossRef]
18. Grover S, Valaparla VL. Venlafaxine induced akathisia: a case report. Indian J Pharmacol 2014; 46:660-661. [CrossRef]
19. Lane RM. SSRI-induced extrapyramidal side-effects and akathisia: implications for treatment. J Psychopharmacol 1998; 12:192-214. [CrossRef]
20. Preskorn S, Patroneva A, Silman H, Jiang Q, Isler JA, Burczynski ME, Ahmed S, Paul J, Nichols AI. Comparison of the pharmacokinetics of venlafaxine extended release and desvenlafaxine in extensive and poor cytochrome P450 2D6 metabolizers. J Clin Psychopharmacol 2009; 29:39-43. [CrossRef]
21. Hedenmalm K, Guzey C, Dahl ML, Yue QY, Spigset O. Risk factors for extrapyramidal symptoms during treatment with selective serotonin reuptake inhibitors, including cytochrome P-450 enzyme, and serotonin and dopamine transporter and receptor polymorphisms. J Clin Psychopharmacol 2006; 26:192- 197. [CrossRef]
22. Garcia-Parajua P, Alverez Iniesta I, Magarinos M. Reversible and dose-related parkinsonism induced by venlafaxine. Med Clin (Barc) 2003; 120:759. (Spanish) [CrossRef]
23. Geber C, Ostad Haji E, Schlicht K, Hiemke C, Tadic A. Severe tremor after cotrimoxazole-induced elevation of venlafaxine serum concentrations in a patient with major depressive disorder. Ther Drug Monit 2013; 35:279-282. [CrossRef]
24. Brown ES, Hong SC. Antidepressant-induced bruxism successfully treated with gabapentin. J Am Dent Assoc 1999; 130:1467-1469. [CrossRef]